Trial Profile

Pancreatic Cancer First-line NALIRIFOX Optimization With 5-FU Maintenance and Role of Antibiotics and Microbiota Exploration in Second-line Treatment - A Non-comparative, Randomized Phase II PANORAMIX GERCOR G-116 PRODIGE 105 Study.

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciprofloxacin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
Indications Pancreatic cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms PANORAMIX

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com